Stocks and Investing Stocks and Investing
Tue, September 26, 2023

Uy Ear Reiterated (SRPT) at Strong Buy and Held Target at $160 on, Sep 26th, 2023


Published on 2024-10-28 06:34:27 - WOPRAI, Uy Ear
  Print publication without navigation


Uy Ear of Mizuho, Reiterated "Sarepta Therapeutics, Inc." (SRPT) at Strong Buy and Held Target at $160 on, Sep 26th, 2023.

Uy has made no other calls on SRPT in the last 4 months.



There are 10 other peers that have a rating on SRPT. Out of the 10 peers that are also analyzing SRPT, 2 agree with Uy's Rating of Hold. Following are those relevant analyst calls for the last 4 months


  • Judah Frommer of "Credit Suisse" Reiterated at Hold and Held Target at $141 on, Friday, June 23rd, 2023
  • Gavin Clark-Gartner of "Evercore ISI Group" Downgraded from Buy to Hold and Held Target at $139 on, Friday, June 23rd, 2023


These are the ratings of the 8 analyists that currently disagree with Uy


  • Brian Abrahams of "RBC Capital" Maintained at Buy with Increased Target to $223 on, Thursday, August 3rd, 2023
  • Gil Blum of "Needham" Reiterated at Strong Buy and Held Target at $185 on, Thursday, August 3rd, 2023
  • Matthew Harrison of "Morgan Stanley" Reiterated at Buy and Held Target at $183 on, Thursday, August 3rd, 2023
  • Neena Bitritto-Garg of "Citigroup" Maintained at Strong Buy with Increased Target to $204 on, Friday, June 23rd, 2023
  • Salveen Richter of "Goldman Sachs" Maintained at Strong Buy with Increased Target to $215 on, Friday, June 23rd, 2023
  • Kristen Kluska of "Cantor Fitzgerald" Maintained at Buy with Increased Target to $166 on, Friday, June 23rd, 2023
  • Anupam Rama of "JP Morgan" Maintained at Buy with Decreased Target to $213 on, Friday, June 23rd, 2023
  • Hartaj Singh of "Oppenheimer" Reiterated at Buy and Held Target at $180 on, Friday, May 26th, 2023
Contributing Sources